Skip to content
DilutionScan
Arcturus Therapeutics Holdings Inc. logo
ARCT$8.04+0.88%

Arcturus Therapeutics Holdings Inc.

Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq

Mkt Cap & EV$251.56M /
Float & O/SPro
Est. Net Cash/Sh
Inst OwnPro

DilutionScan read 28 of Arcturus Therapeutics Holdings Inc.'s SEC filings and found 1 ATM program, 2 shelf registrations and 3 completed offerings on file for ARCT. The latest dilution event on file is an offering on Nov 16, 2026. Analysis updated Nov 18, 2026.

Signal8 Summary

ARCT

Unprofitable biotech with shrinking revenue

What's Happening Right Now

  • : Reported Q2 2026 revenue of $3.0 million, down from the prior year due to a collaboration wind-down, with a net loss of $23.8 million, but regained global rights to its KOSTAIVE COVID-19 vaccine and extended its cash runway through 2028.
  • : Announced a strategic collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.

Snapshot

Arcturus is an unprofitable biotech burning through cash to develop RNA medicines. Revenue dropped 51% in FY 2025 to $67.2M, resulting in a $65.8M net loss and a $74.3M free cash flow burn.

Create a free account to read the rest

DilutionScanEvery instrument in full · From $29.99/mo